BioArctic, Mesenkia partner to develop BrainTransporter-enabled antibody for glioblastoma

Reuters2026/08/19 09:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioArctic entered an oncology research collaboration with Mesenkia to develop an antibody-based treatment concept for glioblastoma.
Work combines BrainTransporter technology with a Mesenkia KITAIbodies antibody targeting HVEM on glioblastoma cells, including stem-like cells.
BioArctic will create a new drug candidate using the combined approach.
Partners plan joint preclinical studies to test the concept, then decide on further development based on results.
Collaboration expands BrainTransporter R&D beyond neurodegeneration into oncology, targeting brain delivery as a key constraint in glioblastoma therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 202608190515BITN____UKPR__SV_20260819-BIT-9480-0) on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioArctic, Mesenkia partner to develop BrainTransporter-enabled antibody for glioblastoma

You may also like

Crypto prices